Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Piroxicam mesotherapy versus methylprednisolone injection for pes anserine tendinobursitis
IRCT20260919071113N1Phase 3Recruiting
- Sponsor
- Isfahan University of Medical Sciences
- Start
- Sep 2026
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, triple-blind trial of piroxicam, methylprednisolone and lidocaine in Pes anserine bursitis (PAB) (2 arms), sponsored by Isfahan University of Medical Sciences. Primary endpoints: Pain severity by Visual Analog Scale, Knee Injury and Osteoarthritis Outcome Score and 1 more. Started Sep 2026; status: recruiting.
02
Drugs
piroxicammethylprednisolonelidocaine
03
Conditions
Pes anserine bursitis (PAB)
Beyond the preview
Go deeper on IRCT20260919071113N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20260919071113N1.